Efficacy of a new mutated recombinant tissue-type plasminogen activator in beagles with acute coronary artery thrombi.

BACKGROUND Development of new coronary thrombolytic agents is hot in the market. A new drug, mutated recombinant tissue-type plasminogen activator (rtPAm), is the product of mutation of tPA by changing binding loci with plasminogen activator inhibitor (PAI)-1 to reduce the degradation. In vitro test has demonstrated that the activity of rtPAm is much higher… (More)